FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
Portfolio Pulse from
Corcept Therapeutics has announced that the FDA has filed its New Drug Application for relacorilant, a selective cortisol modulator, to treat hypercortisolism.
March 03, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics' New Drug Application for relacorilant has been filed by the FDA, marking a significant regulatory step for the treatment of hypercortisolism.
The filing of the NDA by the FDA is a crucial step in the drug approval process, indicating progress in Corcept's product pipeline. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100